The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial.
 
Joseph Tintelnot
No Relationships to Disclose
 
Alexander Stein
Consulting or Advisory Role - Amgen (Inst); AstraZeneca; Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Merck KGaA; MSD (Inst); Novartis (Inst); Roche; SERVIER (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Merck KGaA; Roche; Sanofi; Servier
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pierre Fabre (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck KGaA; Roche
 
Lisa Paschold
No Relationships to Disclose
 
Eray Goekkurt
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; MSD Oncology; Pfizer; Roche Pharma AG
Travel, Accommodations, Expenses - SERVIER
 
Christoph Schultheiß
No Relationships to Disclose
 
Peter C. Thuss-Patience
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Meyers-Squibb; Daiichi Sankyo; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; SERVIER
Research Funding - Merck/Pfizer (Inst)
 
Sylvie Lorenzen
Honoraria - BMS GmbH & Co. KG
Consulting or Advisory Role - BMS GmbH & Co. KG
Speakers' Bureau - BMS GmbH & Co. KG
Research Funding - BMS GmbH & Co. KG (Inst)
 
Thomas Jens Ettrich
Consulting or Advisory Role - AstraZeneca; Bayer; BMS GmbH & Co. KG; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Eisai; Incyte; Ipsen; Lilly; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Baxalta/Shire
Travel, Accommodations, Expenses - Ipsen
 
Jorge Riera Knorrenschild
No Relationships to Disclose
 
Lutz Jacobasch
No Relationships to Disclose
 
Stefan Kubicka
No Relationships to Disclose
 
Salah-Eddin Al-Batran
No Relationships to Disclose
 
Anke C. Reinacher-Schick
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; MCI Group; Merck Serono; MSD; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche
Research Funding - AIO-Studien (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); AstraZeneca (Inst); BioNTech (Inst); Celgene (Inst); ERYTECH Pharma (Inst); Ipsen (Inst); Lilly (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; Pierre Fabre; Pierre Fabre; Roche
 
Daniel Pink
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Deciphera (Inst); PharmaMar (Inst)
Speakers' Bureau - PharmaMar (Inst)
Research Funding - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); PharmaMar (Inst); Roche (Inst)
 
Marianne Sinn
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Incyte; MSD; Pfizer; Pierre Fabre; SERVIER
Research Funding - BMS GmbH & Co. KG (Inst)
 
Udo Lindig
No Relationships to Disclose
 
Axel Hinke
No Relationships to Disclose
 
Susanna Hegewisch-Becker
No Relationships to Disclose
 
Mascha Binder
Honoraria - Amgen; Janssen-Cilag; Merck; MSD
Consulting or Advisory Role - Janssen-Cilag; MSD
Research Funding - Janssen-Cilag; Novartis